Form 4: Sangamo Therapeutics Director Karen L. Smith Reports Acquisition of Shares and Stock Options

Director Karen L. Smith reports acquisition of 25,000 shares of common stock and 50,000 stock options in Sangamo Therapeutics.

Summary

• On June 4, 2024, Karen L. Smith, a director of Sangamo Therapeutics, reported acquiring 25,000 shares of common stock and 50,000 stock options.
• The 25,000 shares were acquired through a restricted stock unit (RSU) grant that will fully vest on the earlier of June 4, 2025, or the day prior to the 2025 annual meeting of stockholders, subject to continuous service.
• The stock options, with an exercise price of $0.5676, are immediately exercisable in full, but unvested shares purchased under the option are subject to repurchase rights by the issuer upon cessation of continuous service.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and stock options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.
• The vesting schedules tied to continuous service incentivize the director to remain with the company.

Risks

• The unvested shares purchased under the option are subject to repurchase rights by the issuer if the director ceases continuous service, which could impact the director's holdings.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a commitment to the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU grants are common forms of executive compensation in the biotechnology industry.
• Vesting schedules tied to continuous service are standard practice to align management's interests with those of shareholders.
• The specific terms of the grants (e.g., exercise price, vesting period) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.
• The vesting schedules tied to continuous service can incentivize employees.

Key Dates